Background and Purpose: Platelet function testing in neurointerventional (NI) procedures is still controversial. We compared the clinical outcomes between antiplatelet responders and nonresponders based on the results of the VerifyNow (VN) testing method. Methods: This is a retrospective single-center analysis of all consecutive patients who underwent NI stenting procedures from January 2007 through July 2013 and had documented preprocedural aspirin (ASA) and clopidogrel VN assays. Patients were divided into two groups based on their responsiveness to antiplatelet. Baseline characteristics, good functional outcome measured by the modified Rankin Scale (mRS) at 90 days, combined procedural complication rate defined as postprocedural stroke, in-stent thrombosis, and intraoperative rupture were compared between the two groups. Results: Our cohort included 37 patients: 26 were in the responder group (RG) and 11 were in the nonresponder group (NRG). Baseline characteristics were similar between the two groups. Even though the combined complication rate was similar between the two groups [NRG: 2/11 (18%) vs. RG: 2/26 (7%); p = 0.33], there was a trend for a higher rate of good functional outcome (90-day mRS: 0-2) in the RG (22/22, 100%) as compared to the NRG (8/10, 80%) (p = 0.0907). Conclusion: Overall, utilizing the VN antiplatelet function testing did not significantly change the clinical outcome after the NI procedures. Larger randomized trials are warranted to provide a better understanding of the utility of the antiplatelet testing in NI stenting procedures.
Introduction
Platelet function testing in neurointerventional (NI) procedures is still controversial. Even though preprocedural antiplatelet assays, theoretically, might lead to a reduced rate of thromboembolic complications, only little evidence exists supporting such practice. Light transmission aggregometry is the gold standard to test for platelet reactivity, but it is usually expensive and not technically practical, which leads to the emergence of multiple bedside assays, such as the VerifyNow (VN), that can reliably test for platelet inhibition for aspirin (ASA) and P2Y12 inhibitors. While ASA resistance is rare, clopidogrel resistance is more challenging as it is reported to be as high as 30-35% in the monitoring cohort and it is usually due, in part, to genetic variation, which is reported to increase the thromboembolic complications even with escalating the dosing of clopidogrel [1] [2] [3] [4] . The cardiology literature representing multiple large multi-center randomized controlled trials did not show an overall clinical outcome benefit of antiplatelet therapy modification based on the preprocedural assays [5, 6] . In the cardiology literature, the end points of complete stent thrombosis and urgent revascularization are oversimplified and should not be applied in isolation to the NI population as this population is also susceptible to other complications including perforator occlusions, symptomatic distal thromboembolism, and subarachnoid and parenchymal hemorrhages.
Methods
We conducted a retrospective review of our prospectively maintained NI database at our University Hospital from January 2007 through July 2013 to identify all NI cases that underwent cervical carotid artery stenting or any other type of intracranial stenting and had documented preprocedural ASA VN and/or P2Y12 antiplatelet assays. Patient data including demographics, antiplatelet regimen, presenting pathology, serologic testing, other medical comorbidities, and periprocedural complications (ipsilateral ischemic events, intra-or extracranial hemorrhagic events, and in-stent thrombosis) were recorded. Platelet function was assessed with the VN ASA and the VN P2Y12 assays (Accumetrics, San Diego, Calif., USA) in ASA reaction units and P2Y12 reaction units (PRU), respectively.
A dual antiplatelet regimen consisting of 325 mg ASA daily and 75 mg clopidogrel daily, starting 7-10 days before the intervention, was given to all patients in this cohort. Even though therapeutic platelet inhibition testing remains controversial, the patients in our cohort were considered responsive if ASA reaction units ≤ 550 and PRU ≤ 237 [7, 8] . Patients were maintained on dual antiplatelets for 3 months after the procedure and then on ASA monotherapy indefinitely. Nonresponders to clopidogrel received intraprocedural intravenous (i.v.) eptifibatide or were loaded with 250 mg ticlopidine before the procedure. The choice of agent was at the discretion of the neurointerventionalist. Patients who did not have documented preprocedural antiplatelet assays were excluded from the final analysis. The records of the rest of the patients were retrieved for analysis. The patients were then divided into two groups based on their preprocedural VN results into responders and nonresponders.
The primary outcome of interest was combined periprocedural complications (ipsilateral ischemic events, intra-or extracranial hemorrhagic events, in-stent thrombosis). The secondary outcomes of interest in the two groups included the good functional outcome defined by modified Rankin Scale (mRS) scores of 0-2 at 90 days after the procedure. IBM SPSS software version 20 was utilized to perform the desired statistical analysis. A simple two-sample t test was performed to compare the age. The χ 2 test of independence was used to compare the rest of the variables between the two groups.
The Institutional Review Board at Rutgers University approved this retrospective study. Values are presented as n (%) unless otherwise indicated. Values are presented as n (%).
Primary and Secondary Clinical Outcomes
The total procedural complication rate (primary end point) was similar across the two groups [NRG: 2/11 (18%) vs. RG: 2/26 (7%); p = 0.33). There were similar rates of in-stent thrombosis [NRG: 0/11 (0%) vs. RG: 1/26 (3%); p = 0.85] and intraoperative aneurysm rupture [NRG: 0/11 (0%) vs. RG: 1/26 (3%); p = 0.85] across both groups. However, the NRG had a trend towards a higher chance of postoperative stroke [NRG: 2/11 (18%) vs. RG: 0/26 (0%); p = 0.083; table 2 ]. Among the 37 patients, only 32 had their functional assessment at 90 days at the time of the analysis (10 patients in the NRG and 22 patients in the RG). There was a trend for a higher rate of good functional outcome (90-day mRS: 0-2) in the RG (22/22, 100%) as compared to the NRG (8/10, 80%) (p = 0.0907; table 2 ).
Discussion
Our analysis adds to the scant evidence of using platelet function tests in NI procedures. Even though our study showed a better overall functional outcome and decreased rates of postoperative stroke in the RG, this might not be completely explained by the antiplatelet responsiveness. This is particularly true given the small number of patients and the pathophysiological diversity of our cohort. While there has been more cardiac and neurological literature to suggest that patients who are resistant to clopidogrel have a higher rate of periprocedural thrombotic complications [3] , there is no solid evidence for routine utility of platelet function tests for patients undergoing NI procedures. The only two randomized clinical trials to look at this were both found in the cardiology literature. In the GRAVITAS trial, resistant patients were randomized to receiving either standard or double-dose clopidogrel after percutaneous coronary intervention [6] . There was no difference in the development of death, myocardiac infarction, or stent thrombosis between the two groups. However, patients were given double-dose clopidogrel and not targeted to a specific PRU level. In the ARCTIC trial, patients with percutaneous coronary intervention were given additional clopidogrel loading or were switched to prasugrel. Again, there was no difference in outcomes. However, PRU < 230 were not achieved in 15% of patients on follow-up testing. As mentioned above, the demographics and risk factors differ among NI and cardiovascular patients. The clinically significant risk of cardiovascular stenting is largely stent thrombosis, whereas in NI patients, hemorrhagic and thromboembolic complications are serious concerns. While these are important differences, lessons can be learned from the similarities in the data. The rates of platelet activity in neurovascular patients on antiplatelet medications have been found to be similar to those in cardiovascular patients [9, 10] . A previous report encompassing 48 procedures with a pipeline embolization device found that a PRU value of >240 predicted thromboembolic events [11] . PRU values <198 were found to have a protective effect against ischemic events in an observational carotid stenting study [4] . Furthermore, reports suggest that a PRU value <60 is associated with an increased hemorrhagic risk [11] . There are limited data in regard to neurovascular patients and modification of treatment. A recent prospective study found a nonsignificant decrease in thromboembolic complications with double dose for patients with ≤ 20% platelet inhibition [3] . Optimal target PRU values for NI procedures have yet to be determined as there is a paucity of high-quality studies specific to NI procedures [12] .
In our cohort, 11 patients were found to be clopidogrel resistant and were given either ticlodipine or eptifibatide. Two of these patients had postoperative stroke. Several reports have shown that platelet inhibition can be increased through different methods in resistant patients. Increasing doses of ASA or clopidogrel may reduce resistance in some patients. In addition, switching to a different antiplatelet agent can also reduce platelet activity. In pa-tients resistant to clopidogrel, double dosing has been shown to result in therapeutic platelet activity in some patients [13] . Nevertheless, this reduction in platelet activity has not decreased thrombotic complications. Also, the overall complication rate in our cohort was similar to what has previously been reported in NI procedures that did not use antiplatelet assays.
As this was a retrospective study, we did not have a set protocol for the universal testing of patients undergoing NI stenting procedures and for modifications of antiplatelet therapy based on non-or hyper-responders. Moreover, we were not able to identify the reasons for preferring either eptifibatide or ticlopidine in the medical records. In our cohort, these medications were used for high platelet activity on antiplatelet testing rather than intraprocedural thrombus. Our study has significant limitations including its retrospective design and relatively small sample size, in addition to the pathophysiological diversity of the cohort. However it calls into question important aspects of NI stenting procedures and sheds light on the importance of validating the newer antiplatelet function testing.
Conclusion
Overall, the utilization of the VN antiplatelet function testing did not significantly change the clinical outcome after NI procedures. This echoes the scant literature that advocates against the use of antiplatelet assays for the general population undergoing such procedures. Larger randomized trials are warranted to provide a better understanding of the utility of antiplatelet testing in NI stenting procedures.
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